Nuvation Bio Inc (NUVB) Stock Price, Quote & News

Company Profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against place...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 208 6102

Website: www.nuvationbio.com

Address:

1500 Broadway, Suite 1401, New York, United States

njbugatti Jul. 23 at 11:38 PM

$NUVB https://m.youtube.com/watch?v=sQB9o5NGZOw&pp=ygUZRGF2ZSBiam9yayB3aXRoIGRyIG5hc3Nlcg%3D%3D&ra=m

0 · Reply

Belisimo Jul. 23 at 2:11 PM

$NUVB How about this? Hung sells ibtrozi to big pharma and let them battle it out with GSK. Concentrate on developing Safusidenib ,DDC, and buying another potential asset blockbuster. 1 billion for ibtrozi? I'm just throwing this out there.

4 · Reply

JuggernautRaider Jul. 23 at 1:50 PM

$TNXP just imagine if Tonix had a CEO like David Hung of $NUVB 😳

0 · Reply

dixiebull Jul. 23 at 1:06 PM

$ADVB $PYXS $NUVB $LABT $PN ADVB as usual the first one on my watchlist is the nicest

0 · Reply

dixiebull Jul. 23 at 11:18 AM

$ADVB $PYXS $NUVB $LABT $PN ADVB first on watchlist, as ususal

0 · Reply

JuggernautRaider Jul. 23 at 3:41 AM

$TNXP $NUVB $MIST $IMRX Well, You are Welcome! 🤗

0 · Reply

Paul_Volcker Jul. 23 at 3:36 AM

$NUVB Last day it closed at $6.55 or higher - Jan 13th

0 · Reply

Paul_Volcker Jul. 23 at 2:29 AM

$NUVB It looks like the Jideytro press release hit the wire at 1:58. The low for the day - $6.03 - was at around 2:45. Some good size purchases started to hit at 2:53 and continued into the close driving the price up. Just making some observations.

1 · Reply

JuggernautRaider Jul. 23 at 1:32 AM

$MIST thinking of loading up like I did $NUVB and $IMRX and $CCCC at $1.50 🧐

0 · Reply

ConsulHorkos Jul. 23 at 12:14 AM

$NUVB with all the GSK excitement (previously treated) I almost missed that we are finally doing a ER premarket. Might be something or could be nothing but I always prefer morning ER.

0 · Reply

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

2026-07-20T15:05:17.000Z - 3 days ago

RBC looks for Nuvation shares to appreciate as safusidenib data builds

Jul 20, 2026, 9:00 AM EDT - 3 days ago

Nuvation Bio Slides: Corporate presentation

2026-07-20T12:05:16.000Z - 3 days ago

Nuvation Bio announces data from the Phase 2 J201 study

Jul 20, 2026, 8:00 AM EDT - 3 days ago

Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma

2026-07-09T21:29:02.000Z - 14 days ago

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

ABCL SERV UBER

2026-07-07T11:35:44.000Z - 16 days ago

Nuvation Bio price target lowered to $19 from $20 at RBC Capital

Jul 6, 2026, 5:09 PM EDT - 17 days ago

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

2026-06-29T12:05:27.000Z - 24 days ago

Nuvation Bio announces MHRA in UK approves MAA for taletrectinib

Jun 29, 2026, 8:00 AM EDT - 24 days ago

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom

2026-06-26T11:20:42.000Z - 27 days ago

Nuvation Bio prices upsized offering of $250M of convertible senior notes

Jun 25, 2026, 11:58 PM EDT - 27 days ago

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

2026-06-25T14:05:38.000Z - 4 weeks ago

Nuvation Bio falls -10.1%

2026-06-25T11:10:33.000Z - 4 weeks ago

Nuvation Bio files to sell $200M of Convertible Senior Notes due 2032

Jun 25, 2026, 7:00 AM EDT - 4 weeks ago

Nuvation Bio Announces Proposed Convertible Senior Notes Offering

Jun 15, 2026, 7:00 AM EDT - 5 weeks ago

Nuvation Bio Slides: Corporate presentation

Jun 3, 2026, 9:55 AM EDT - 7 weeks ago

Nuvation Bio Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 4:05 PM EDT - 2 months ago

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

2026-05-27T14:37:32.000Z - 2 months ago

Nuvation Bio’s Ibtrozi shows improved quality of life in NSCLC trial

May 27, 2026, 8:00 AM EDT - 2 months ago

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting

May 26, 2026, 12:00 PM EDT - 2 months ago

Nuvation Bio Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 21, 2026, 11:00 AM EDT - 2 months ago

Nuvation Bio Transcript: AGM 2026

May 20, 2026, 9:00 AM EDT - 2 months ago

Nuvation Bio Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 1:30 PM EDT - 2 months ago

Nuvation Bio Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

2026-05-13T20:41:35.000Z - 2 months ago

Nuvation Bio collaborating with Thermo Fisher to manufacture Ibtrozi in NSCLC

TMO

May 13, 2026, 4:05 PM EDT - 2 months ago

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer

May 13, 2026, 11:00 AM EDT - 2 months ago

Nuvation Bio Transcript: Bank of America Global Healthcare Conference 2026

2026-05-07T06:20:14.000Z - 2 months ago

Nuvation Bio: FDA accepts sNDA with updated data for IBTROZI

May 6, 2026, 8:00 AM EDT - 2 months ago

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer

May 5, 2026, 4:05 PM EDT - 2 months ago

Nuvation Bio to Participate in Upcoming Investor Conferences

May 4, 2026, 4:30 PM EDT - 2 months ago

Nuvation Bio Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

Nuvation Bio Quarterly report: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

Nuvation Bio Earnings release: Q1 2026

2026-05-04T20:17:35.000Z - 2 months ago

Nuvation Bio reports Q1 EPS 1c, consensus 5c

May 4, 2026, 4:10 PM EDT - 2 months ago

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

May 4, 2026, 4:00 PM EDT - 2 months ago

Nuvation Bio Slides: Investor presentation

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

2026-04-21T22:05:15.000Z - 3 months ago

Nuvation Bio reports results from TRUST-I and TRUST-II trials for IBTROZI

Apr 21, 2026, 6:00 PM EDT - 3 months ago

Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Nuvation Bio Proxy statement: Proxy filing

Apr 21, 2026, 7:00 AM EDT - 3 months ago

Nuvation Bio Slides: Corporate presentation

Apr 20, 2026, 4:05 PM EDT - 3 months ago

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Nuvation Bio Proxy statement: Proxy filing

2026-04-01T12:16:16.000Z - 4 months ago

Nuvation Bio amends license agreement for safusidenib with Daiichi Sankyo

Apr 1, 2026, 8:00 AM EDT - 4 months ago

Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo

2026-03-26T20:10:15.000Z - 4 months ago

Nuvation Bio and Eisai’s MAA for taletrectinib in NSLC accepted in Europe

Mar 26, 2026, 4:05 PM EDT - 4 months ago

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

Mar 17, 2026, 4:35 PM EDT - 4 months ago

Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026

Mar 11, 2026, 8:25 AM EDT - 4 months ago

Nuvation Bio Transcript: The Citizens Life Sciences Conference 2026

2026-03-04T17:05:33.000Z - 5 months ago

Nuvation Bio falls -25.3%

Mar 4, 2026, 10:30 AM EST - 5 months ago

Nuvation Bio Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-04T15:08:39.000Z - 5 months ago

Nuvation Bio falls -25.3%

Mar 4, 2026, 8:30 AM EST - 5 months ago

Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-03-03T17:00:18.000Z - 5 months ago

Nuvation Bio falls -25.6%

2026-03-03T15:06:52.000Z - 5 months ago

Nuvation Bio falls -26.1%

Mar 2, 2026, 4:30 PM EST - 5 months ago

Nuvation Bio Earnings Call Transcript: Q4 2025

Mar 2, 2026, 4:30 PM EST - 5 months ago

Nuvation Bio Annual report: Q4 2025

Mar 2, 2026, 4:30 PM EST - 5 months ago

Nuvation Bio Earnings release: Q4 2025

Mar 2, 2026, 4:05 PM EST - 5 months ago

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 2, 2026, 7:00 AM EST - 5 months ago

Nuvation Bio Slides: Corporate presentation

Feb 17, 2026, 4:05 PM EST - 5 months ago

Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026

Feb 9, 2026, 8:00 AM EST - 5 months ago

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma

Jan 22, 2026, 10:26 AM EST - 6 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 13, 2026, 6:45 PM EST - 6 months ago

Nuvation Bio Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 6 months ago

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 6 months ago

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

Jan 12, 2026, 7:00 AM EST - 6 months ago

Nuvation Bio Slides: Corporate presentation

Jan 6, 2026, 4:05 PM EST - 7 months ago

Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 6, 2025, 10:40 PM EST - 8 months ago

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

Dec 3, 2025, 9:00 AM EST - 8 months ago

Nuvation Bio Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 8:00 AM EST - 8 months ago

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

Dec 2, 2025, 9:35 AM EST - 8 months ago

Nuvation Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 7:00 AM EST - 8 months ago

Nuvation Bio Slides: Corporate Presentation

Nov 19, 2025, 10:00 AM EST - 8 months ago

Nuvation Bio Transcript: Jefferies London Healthcare Conference 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Nuvation Bio Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Nuvation Bio Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Nuvation Bio Earnings release: Q3 2025

Nov 3, 2025, 4:05 PM EST - 9 months ago

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 2, 2025, 12:00 AM EDT - 9 months ago

Nuvation Bio Slides: Corporate Presentation

Oct 23, 2025, 7:30 AM EDT - 9 months ago

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Oct 20, 2025, 4:05 PM EDT - 9 months ago

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

Sep 30, 2025, 7:30 AM EDT - 10 months ago

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Sep 19, 2025, 7:30 AM EDT - 10 months ago

Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Sep 9, 2025, 11:30 AM EDT - 11 months ago

Nuvation Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 7, 2025, 6:00 AM EDT - 11 months ago

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

Sep 4, 2025, 2:10 PM EDT - 11 months ago

Nuvation Bio Transcript: Cantor Global Healthcare Conference 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Nuvation Bio Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Nuvation Bio Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Nuvation Bio Earnings release: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 1 year ago

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 6:00 PM EDT - 1 year ago

Nuvation Bio Slides: Corporate Presentation

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Jul 24, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jun 24, 2025, 7:00 AM EDT - 1 year ago

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

Jun 16, 2025, 7:30 AM EDT - 1 year ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

Jun 12, 2025, 7:30 AM EDT - 1 year ago

Nuvation Bio Transcript: FDA Announcement

Jun 12, 2025, 7:30 AM EDT - 1 year ago

Nuvation Bio Press release: FDA Announcement

Jun 12, 2025, 7:30 AM EDT - 1 year ago

Nuvation Bio Slides: FDA Announcement

Jun 11, 2025, 1:45 PM EDT - 1 year ago

US FDA approves Nuvation Bio's lung cancer therapy

Jun 11, 2025, 1:20 PM EDT - 1 year ago

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

May 28, 2025, 3:30 PM EDT - 1 year ago

Nuvation Bio Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 21, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

May 21, 2025, 1:35 PM EDT - 1 year ago

Nuvation Bio Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 3:00 PM EDT - 1 year ago

Nuvation Bio Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 13, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

May 8, 2025, 10:00 AM EDT - 1 year ago

Nuvation Bio Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Nuvation Bio Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Nuvation Bio Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Nuvation Bio Earnings release: Q1 2025

May 7, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio to Present at The Citizens Life Sciences Conference

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

Apr 9, 2025, 1:00 PM EDT - 1 year ago

Nuvation Bio Transcript: Jones Healthcare And Technology Innovation Conference

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Nuvation Bio Proxy statement: Proxy Filing

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

njbugatti Jul. 23 at 11:38 PM

$NUVB https://m.youtube.com/watch?v=sQB9o5NGZOw&pp=ygUZRGF2ZSBiam9yayB3aXRoIGRyIG5hc3Nlcg%3D%3D&ra=m

0 · Reply

Belisimo Jul. 23 at 2:11 PM

4 · Reply

JuggernautRaider Jul. 23 at 1:50 PM

$TNXP just imagine if Tonix had a CEO like David Hung of $NUVB 😳

0 · Reply

dixiebull Jul. 23 at 1:06 PM

$ADVB $PYXS $NUVB $LABT $PN ADVB as usual the first one on my watchlist is the nicest

0 · Reply

dixiebull Jul. 23 at 11:18 AM

$ADVB $PYXS $NUVB $LABT $PN ADVB first on watchlist, as ususal

0 · Reply

JuggernautRaider Jul. 23 at 3:41 AM

$TNXP $NUVB $MIST $IMRX Well, You are Welcome! 🤗

0 · Reply

Paul_Volcker Jul. 23 at 3:36 AM

$NUVB Last day it closed at $6.55 or higher - Jan 13th

0 · Reply

Paul_Volcker Jul. 23 at 2:29 AM

1 · Reply

JuggernautRaider Jul. 23 at 1:32 AM

$MIST thinking of loading up like I did $NUVB and $IMRX and $CCCC at $1.50 🧐

0 · Reply

ConsulHorkos Jul. 23 at 12:14 AM

$NUVB with all the GSK excitement (previously treated) I almost missed that we are finally doing a ER premarket. Might be something or could be nothing but I always prefer morning ER.

0 · Reply

Incognito_21 Jul. 22 at 11:19 PM

$NUVB longs wait until September if we get that far

0 · Reply

Bio_Invest101 Jul. 22 at 9:30 PM

$NUVB GSK official statement today You all read it like Dr Hung’s doing now. What’d you say ? https://www.gsk.com/en-gb/media/press-releases/jideytro-zidesamtinib-approved-in-the-us-for-previously-treated-ros1-positive-non-small-cell-lung-cancer/

0 · Reply

ak123456790 Jul. 22 at 9:09 PM

$NUVB GSK drug will be used after Ibtrozi so there is no current competition! They have also a very small trial that is currently on going that is on the same field as Introzi but the results are worser . It will take at least 5 years to show ( if they can) similar results as Hungs drug! Remember that we have 50months which no other drug has or will have in the long future! Keep calm and accumulate the cheapies!

2 · Reply

dixiebull Jul. 22 at 8:52 PM

$ADVB see if 10 can hold now for another run to 13 and 15 $PYXS nice move to 2.56, if that 2.50 holds it can see 3 to 3.25 $NUVB bounced off 6 to 6.60, see if 6.35 holds for a move to 7 and 7.50 $LABT sitting at 3.50 so watch for volume for a move to 5 $PN nice break of 10 to 11.50, see if 8.50 holds now for a move to 10 and 12

1 · Reply

njbugatti Jul. 22 at 8:49 PM

$NUVB That’s a Hell of a V! Very…..

0 · Reply

Bio_Invest101 Jul. 22 at 8:42 PM

$NUVB Unbelievable remarks by GSK CSO But I love the “50,000 new cases” every year !!! Let’s the competition begins!!!! And time for Dr Hung to rise up to meet the GSK challenges https://www.fiercepharma.com/pharma/gsk-secures-first-ever-lung-cancer-fda-approval-jideytro-nuvalent-deal

2 · Reply

Belisimo Jul. 22 at 8:29 PM

$NUVB This early approval was not expected this early that's my opinion. Anyone attempting to sugarcoat this ......well nothing more on that. GSK using it's clout to get early approval? Why? Look at taletrectinib results. What's better? Why the early approval?

1 · Reply

Bio_Invest101 Jul. 22 at 8:08 PM

$NUVB Mark it 08/06/2026 8:00 AM ET https://investors.nuvationbio.com/news/news-details/2026/Nuvation-Bio-to-Report-Second-Quarter-2026-Financial-Results-and-Provide-Business-Update-on-August-6-2026/default.aspx

0 · Reply

Stevekill Jul. 22 at 8:00 PM

$NUVB what just happened? Checked this morning and it looked like we were going back to the 5’s. 🚀 💯

0 · Reply

marti837 Jul. 22 at 7:38 PM

$NUVB news ah.?

0 · Reply

ejz92 Jul. 22 at 7:26 PM

$NUVB Nice turn of events! Guess the real investors were not shaken out by the expected GSK approval and know what they own.

0 · Reply

copywrites Jul. 22 at 7:24 PM

$NUVB 🎈

1 · Reply

Market Cap	2.24B
Revenue (ttm)	62.90M
Net Income (ttm)	-204.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-325.33%
Debt to Equity Ratio	0.17

Volume	4,261,700
Avg Vol	6,651,942
Day's Range	N/A - N/A
Shares Out	348.20M
Stochastic %K	94%
Beta	1.52
Analysts	Strong Sell
Price Target	$12.55